Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis

Zhai, Duanyang; Zhou, Yu; Kuang, Xiaying; Shao, Fangyuan; Zhen, Tiantian; Lin, Ying; Wang, Qing; Shao, Nan

doi:10.7150/ijms.86969



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2023; 20(9):1152-1162. doi:10.7150/ijms.86969 This issue Cite

Research Paper

Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis

Duanyang Zhai^1†, Yu Zhou^1,2†, Xiaying Kuang¹, Fangyuan Shao³, Tiantian Zhen⁴, Ying Lin¹, Qing Wang^5✉, Nan Shao^1✉

1. Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
2. Division of Vascular Surgery, National-Local Joint Engineering Laboratory of Vascular Disease Treatment, Engineering and Technology Center for Diagnosis and Treatment of Vascular Diseases, Guangdong Engineering Laboratoty of Diagnosis and Treatment of Vascular Disease, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
3. Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China.
4. Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
5. Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
†Duanyang Zhai and Yu Zhou contributed equally to this work

Citation:

Zhai D, Zhou Y, Kuang X, Shao F, Zhen T, Lin Y, Wang Q, Shao N. Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis. Int J Med Sci 2023; 20(9):1152-1162. doi:10.7150/ijms.86969. https://www.medsci.org/v20p1152.htm

Other styles

Abstract

Background: Long noncoding RNAs (lncRNAs) substantially affect tumor metastasis and are aberrantly expressed in various cancers. However, its role in breast cancer (BC) remains unclear.

Methods: A microarray assay of differentially expressed lncRNAs in epithelial-mesenchymal transition (EMT) and non-EMT cells was performed. The prognostic value of lnc NR2F1-AS1 expression in patients with BC was analyzed using The Cancer Genome Atlas database. Lnc NR2F1-AS1 expression levels in different BC cell lines were assessed using quantitative real-time PCR. The role of lnc NR2F1-AS1 in BC cell metastasis was investigated in vitro and in vivo. Dual luciferase reporter assay and RNA immunoprecipitation were performed to investigate the relationship between lnc NR2F1-AS1, miR-25-3p, and ZEB2.

Results: High levels of lnc NR2F1-AS1 were observed in BC cells undergoing EMT and were closely correlated with adverse prognosis in patients with BC. Lnc NR2F1-AS1 knockdown significantly inhibited BC cell migration, invasiveness in vitro, and metastasis in vivo. Mechanistically, lnc NR2F1-AS1 competitively binds to miR-25-3p to impede ZEB2 degradation, a positive EMT transcription factor in BC.

Conclusions: Our study revealed a novel lnc NR2F1-AS1/miR-25-3p/ZEB2 axis in BC metastasis and that lnc NR2F1-AS1 may serve as a potential therapeutic target for BC metastasis.

Keywords: Lnc NR2F1-AS1, miR-25-3p, ZEB2, metastasis, breast cancer

Citation styles

APA

Zhai, D., Zhou, Y., Kuang, X., Shao, F., Zhen, T., Lin, Y., Wang, Q., Shao, N. (2023). Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis. International Journal of Medical Sciences, 20(9), 1152-1162. https://doi.org/10.7150/ijms.86969.

ACS

Zhai, D.; Zhou, Y.; Kuang, X.; Shao, F.; Zhen, T.; Lin, Y.; Wang, Q.; Shao, N. Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis. Int. J. Med. Sci. 2023, 20 (9), 1152-1162. DOI: 10.7150/ijms.86969.

NLM

CSE

Zhai D, Zhou Y, Kuang X, Shao F, Zhen T, Lin Y, Wang Q, Shao N. 2023. Lnc NR2F1-AS1 Promotes Breast Cancer Metastasis by Targeting the MiR-25-3p/ZEB2 Axis. Int J Med Sci. 20(9):1152-1162.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.